Bryn Mawr Trust Advisors LLC Increases Stock Holdings in Becton, Dickinson and Company $BDX

Bryn Mawr Trust Advisors LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 43.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 48,647 shares of the medical instruments supplier’s stock after acquiring an additional 14,631 shares during the quarter. Bryn Mawr Trust Advisors LLC’s holdings in Becton, Dickinson and Company were worth $9,105,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of BDX. SOA Wealth Advisors LLC. grew its holdings in shares of Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the last quarter. Activest Wealth Management boosted its position in shares of Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 97 shares during the period. Bell Investment Advisors Inc grew its stake in Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 128 shares during the last quarter. Grey Fox Wealth Advisors LLC acquired a new position in Becton, Dickinson and Company during the third quarter worth approximately $32,000. Finally, Bank of Jackson Hole Trust boosted its holdings in shares of Becton, Dickinson and Company by 85.6% in the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 95 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the sale, the director owned 35,816 shares in the company, valued at $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 2,680 shares of company stock valued at $539,848 in the last quarter. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $203.56 on Friday. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company has a 50-day moving average price of $198.54 and a 200 day moving average price of $191.24. The company has a market cap of $58.00 billion, a P/E ratio of 34.92, a PEG ratio of 2.22 and a beta of 0.23. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business had revenue of $5.89 billion during the quarter, compared to the consensus estimate of $5.91 billion. During the same period in the prior year, the business posted $3.81 EPS. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company announced that its board has approved a stock repurchase program on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

Analysts Set New Price Targets

BDX has been the subject of several research reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Royal Bank Of Canada upped their target price on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a report on Wednesday, December 17th. Stifel Nicolaus raised their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Piper Sandler boosted their price target on Becton, Dickinson and Company from $190.00 to $205.00 and gave the company a “neutral” rating in a research report on Wednesday. Finally, Jefferies Financial Group increased their price objective on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Four investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $209.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.